Sequanta and Neukio Announce Strategic Collaboration to Advance Immune Cell Therapy Development

December 2021, ShanghaiThe 23rdPR Newswire -- December 22, 2021, SEQUANTA (hereinafter referred to as "SEQUANTA") reached a strategic cooperation with Xingyiang (Shanghai) Biotechnology Co., Ltd. (hereinafter referred to as "Xingyiang Biotech"). Dr. Wang Liqun, founder, chairman and CEO of Xingyiang Biotech, Vice President of R&D, Dr. Zhang Lei; Dr. Sun Lele, founder and CEO of SEQUANTA, and Dr. Li Yuan, General Manager of SEQUANTA, attended the "Opening Ceremony of Xingyiang Biotech R&D and Production Center" and signed the Strategic Cooperation Agreement.

SEQUANTA and Xingyiang (Shanghai) Biotechnology Co., Ltd. Sign Strategic Cooperation Agreement

Immuno-cell therapy is one of the hottest research fields today. The collaboration between SEQUANTA and Xingyiang (Shanghai) Biotechnology Co., Ltd., a company specializing in the development of novel immune cell therapies, aims to leverage SEQUANTA's multi-omics testing technology along with its robust bio-computing and data processing capabilities. This partnership will provide comprehensive testing technical support for Xingyiang in areas such as process development, product testing and analysis, precise disease diagnosis, and dynamic monitoring, thereby accelerating the iteration and research of cell therapy products.

Comprehensive detection technologies for the development of gene and cell therapy products cover the most common vector sequencing, insertion site analysis, CRISPR on-target and off-target analysis, etc. At the same time, SEQUANTA can also leverage its extensive experience in the NGS field to provide customized solutions for customers.

Currently, SEQUANTA is developing for Xingyiang (Shanghai) Biotechnology Co., Ltd.Based onCustomized Solutions for WGS Technology, other projects are also proceeding in an orderly manner.

Dr. Lixun Wang, Founder, Chairman and CEO of Xingyiang (Shanghai) Biotechnology Co., Ltd.

At the inauguration ceremony, Dr. Wang Liqun, founder of Xingyiang (Shanghai) Biotechnology Co., Ltd., stated, "Xingyiang Bio is a company focused on the research and industrialization of immune cell drugs, dedicated to developing chimeric antigen receptor allogeneic NK cell therapies (Allo-CAR-NK) with universal 'off-the-shelf' potential for the treatment of solid tumors."

We believe that as long as we start from the goal, finding appropriate cooperation paths can greatly accelerate the time to solve problems. Therefore, under the condition of having innovative technology research and development ourselves, we also adopt an open cooperation model, mutually introducing and collaborating with globally leading companies. We believe that in the future, with the friendly interaction with SEQUANTA, the development of more allogeneic off-the-shelf immune cell new products will be expedited, providing hope of a cure for cancer patients in China."

Left: Dr. Lele Sun, Founder and CEO of SEQUANTA; Right: Dr. Liqun Wang, Founder, Chairman and CEO of Xingyiang (Shanghai) Biotechnology Co., Ltd.

Dr. Sun Lele, founder and CEO of SEQUANTA, stated, "Cell therapy will be an important weapon for humanity in the fight against cancer. CAR-NK is the latest field in cell therapy and, as an allogeneic universal cell therapy, has the potential for large-scale production."

It is a great honor to become an important partner of Xingyiang (Shanghai) Biotechnology Co., Ltd. in accelerating technology accumulation and achieving efficient innovation. The SEQUANTA R&D team will fully support the project development of Xingyiang (Shanghai) Biotechnology Co., Ltd., integrating innovative concepts into the development and optimization of technical platforms as well as the development of product pipelines.To provide strong support for the rapidly growing innovative drug research and development business of Xingyiang (Shanghai) Biotechnology Co., Ltd.

SEQUANTA's innovative multi-omics technology can be applied to scientific research and drug development in the fields of oncology, immunology, neuroscience, infectious diseases, cardiovascular, metabolism, and reproductive health. Relying on its original innovation advantages and supported by international cutting-edge platforms such as Olink, 10x Genomics, and Mission Bio, SEQUANTA provides customers—including research institutions, hospitals, and pharmaceutical R&D centers—with advanced technical services in multi-dimensional omics, including single-cell genomics, transcriptomics, epigenomics, and proteomics.

"Establishing cooperation with Xingyiang (Shanghai) Biotechnology Co., Ltd. marks another milestone in our expansion within the immune cell therapy field. Adhering to the mission of providing a high-quality service platform, we will continue to create higher value for our partners and further empower the research and development of original new drugs in China."